Beijing CapitalBio Technology Co., Ltd.
company profiles
Beijing CapitalBio Technology Co., Ltd. is a leading life science company that develops and commercializes total health-care solutions. Our company provides a comprehensive portfolio of top-quality products to a diverse customer base ranging from biomedical researchers to healthcare professionals. Our products include an innovative and broad spectrum of microfluidic chips and related instruments, software and databases, reagents and consumables for basic and translational research, drug development, clinical diagnostics, biosafety and food safety, and molecular breeding.
As a core subsidiary of CapitalBio Corporation and the Biological Chip Beijing National Engineering Research Center, CapitalBio Technology was registered in August 2012 and is headquartered in Economic-Technological Development Area in Beijing. With more than 150,000 square meters of office space, CapitalBio Technology employs more than 2000 employees; 60 percent of these employees have at least Bachelor-level degrees, 41 of which are doctors or post-doctorates.
We strive to meet the challenges we face by centering our company around collaborative interaction, efficient problem-solving, and consistent customer satisfaction. With rapid advances in technology apparent and imminent, we recognize that it is crucial to offer solutions that are not only original and inventive, but also flexible and scalable and backed by industry-leading support and services. As a pioneer in its field and industry, CapitalBio Technology is able to provide these services for the research community in genomics, proteomics and metabolomics.
企业简介
北京博奥晶典生物技术有限公司(以下简称“博奥晶典”)是博奥生物集团有限公司暨生物芯片北京国家工程研究中心的产业化平台，是清华大学布局生命健康领域的核心企业。博奥晶典注册成立于2012年8月，在北京、上海、重庆、成都、东莞、香港与美国圣地亚哥等地，拥有生物芯片和仪器设备的生产、研发基地和营销、运营中心，总办公面积超过15万㎡，员工2000余人。
博奥晶典始终坚持自主创新和成果转化，立足新一代生物检测技术，拥有研发、生产、销售以及全国第三方独立医学检验所服务为一体的完整产业链;并响应国家关于“预防为主”的健康方针，将现代医学与中国传统医学紧密结合，打造出集健康产品、健康管理、医疗康复和大数据于一体的大健康产业版块。目前，博奥晶典旗下包括北京博奥医学检验所有限公司、东莞博奥木华基因科技有限公司、重庆博奥新景医学科技有限公司、博奥颐和健康科学技术(北京)有限公司等子公司，多样化的集团运行架构，凸显博奥晶典在生命科学领域立体化产业发展的优势和影响力。
博奥晶典依托清华大学和生物芯片北京国家工程研究中心雄厚的研发实力，获得国内外专利授权400余项，专利转化率近50%。已成功开发出生物芯片及相关试剂耗材、仪器设备、软件数据库、生命科学服务、临床检验服务、健康管理等系列数十项具有自主知识产权的产品和服务。产品获得CFDA、CE 、GS、CB等国内外各类认证证书120余项。公司先后获得中国合格评定国家认可委员会实验室认证、德国莱茵质量管理体系认证、美国组织相容性及遗传学协会(ASHI)认证。
近年来，博奥晶典紧紧围绕健康中国战略，重点关注出生缺陷和慢病健康管理，构建了以23家国家基因检测技术应用示范中心为基础的出生缺陷防控体系和以社区慢病健康管理中心为平台的慢病管理体系。坚持以基层为重点，预防为主，中西医并重，协助地方政府完成慢病中长期规划及健康2030慢病规划目标，建设创新型国家慢病防控示范区，推动健康产业发展，增强人民获得感和幸福感，降低由慢病导致的直接与间接经济负担。
未来，博奥晶典将打造全生命周期、全方位的健康服务体系，开创适合中国国情的医疗健康服务新模式，以多元化的健康产品普惠民生，助力“健康中国”建设。
